Clarification
This article was originally published in The Gold Sheet
Executive Summary
The guidance FDA is developing on testing for oversulfated chondroitin sulfate is a draft that will apply to crude heparin, not heparin drug product. An article in the June 2010 issue of "The Gold Sheet" was unclear